The demonstration that recombinant monoclonal IgA antibodies directed against AD‐2 can neutralize HCMV infection in vitro argues that IgA antibodies should be considered another component of protective immunity to HCMV via AD‐2. The gene discussed is CD79A; the disease is cytomegalovirus infection.